That’s the headline in a sobering article published by Endpoints News on Oct. 31 as many independents are losing money, thanks to reimbursement rates coming in below acquisition costs, on glucagon-like peptide-1 receptor agonists like Novo Nordisk’s Ozempic and Wegovy, as well as Eli Lily’s Mounjaro. It’s backed up by NCPA’s own recent informal survey of pharmacists, with a whopping 95 percent reporting they were paid an average of $42 below cost to acquire GLP-1s. As a result, and as the survey also showed, nearly three quarters of respondents have turned patients away because they were losing money on the deal.
NCPA
